Clinical trial
A 36-Week Extension to Protocol ISA04-03
NCT00258713 · Aurinia Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT00258713 |
|---|---|
| Title | A 36-Week Extension to Protocol ISA04-03 |
| Official title | A 36-Week Extension to Protocol ISA04-03 to Evaluate the Safety and Efficacy of ISA247 in Patients With Plaque Psoriasis |
| Acronym | SPIRIT |
| Lead sponsor | Aurinia Pharmaceuticals Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | voclosporin |
| Enrollment | 309 |
| Start date | Sep 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Nov 28, 2005 |
| Last update posted | Sep 29, 2008 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: